Session

IBD (Posters)

ANCA-ASSOCIATED VASCULITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: ONE OF THE PREDICTORS OF SEVERE COURSE AND REASONS FOR NON-RESPONSE TO BASIC THERAPY
ANCA-ASSOCIATED VASCULITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: ONE OF THE PREDICTORS OF SEVERE COURSE AND REASONS FOR NON-RESPONSE TO BASIC THERAPY

IBD (Posters)  et al.

COMPARATIVE ASSESSMENT OF INFLIXIMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARATIVE ASSESSMENT OF INFLIXIMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

A PILOT STUDY ON THE USE OF USTEKINUMAB IN REFRACTORY PERIANAL CROHN’S DISEASE
A PILOT STUDY ON THE USE OF USTEKINUMAB IN REFRACTORY PERIANAL CROHN’S DISEASE

IBD (Posters)  et al.

PREVALENCE OF FIRST TIME SURGERY AMONGST INFLAMMATORY BOWEL DISEASE PATIENTS AT A DISTRICT GENERAL HOSPITAL: A 25 YEAR RETROSPECTIVE REVIEW
PREVALENCE OF FIRST TIME SURGERY AMONGST INFLAMMATORY BOWEL DISEASE PATIENTS AT A DISTRICT GENERAL HOSPITAL: A 25 YEAR RETROSPECTIVE REVIEW

IBD (Posters)  et al.

REDO-SURGERY IN IBD PATIENTS: WHAT IS THE TIME INTERVAL AND IS THIS EFFECTED BY SPECIFIC RISK FACTORS?
REDO-SURGERY IN IBD PATIENTS: WHAT IS THE TIME INTERVAL AND IS THIS EFFECTED BY SPECIFIC RISK FACTORS?

IBD (Posters)  et al.

PLATELET-TO-LYMPHOCYTE RATIO INDEX: STILL NOT ABOVE FECAL CALPROTECTIN FOR NON-INVASIVE ASSESSMENT OF ENDOSCOPIC ACTIVITY IN ULCERATIVE COLITIS
PLATELET-TO-LYMPHOCYTE RATIO INDEX: STILL NOT ABOVE FECAL CALPROTECTIN FOR NON-INVASIVE ASSESSMENT OF ENDOSCOPIC ACTIVITY IN ULCERATIVE COLITIS

IBD (Posters)  et al.

THE CHANGING TRENDS SEEN WITH SURGERY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE OVER A 25 YEAR REVIEW PERIOD
THE CHANGING TRENDS SEEN WITH SURGERY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE OVER A 25 YEAR REVIEW PERIOD

IBD (Posters)  et al.

DOES THE TYPE OF SURGERY OR DISEASE LOCATION PREDICT THE NEED FOR SUBSEQUENT SURGERIES, IN IBD PATIENTS
DOES THE TYPE OF SURGERY OR DISEASE LOCATION PREDICT THE NEED FOR SUBSEQUENT SURGERIES, IN IBD PATIENTS

IBD (Posters)  et al.

MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

IBD (Posters)  et al.

CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE
CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE

IBD (Posters)  et al.

INCIDENCE, CLINICAL PRESENTATION, AND SEVERITY OF SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN THE “SECOND AND THE THIRD WAVE” OF INFECTION
INCIDENCE, CLINICAL PRESENTATION, AND SEVERITY OF SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN THE “SECOND AND THE THIRD WAVE” OF INFECTION

IBD (Posters)  et al.

PREVALENCE AND RISK FACTORS FOR MALIGNANCY IN INFLAMMATORY BOWEL DISEASE
PREVALENCE AND RISK FACTORS FOR MALIGNANCY IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

EFFICACY OF SUBCUTANEOUS INFLIXIMAB IN PERIANAL CROHN’S DISEASE
EFFICACY OF SUBCUTANEOUS INFLIXIMAB IN PERIANAL CROHN’S DISEASE

IBD (Posters)  et al.

THE INFLAMMATORY BOWEL DISEASE – DISK TOOL FOR ASSESSING DISABILITY IN INFLAMMATORY BOWEL DISEASE PATIENTS: VALIDATION OF THE GREEK VERSION
THE INFLAMMATORY BOWEL DISEASE – DISK TOOL FOR ASSESSING DISABILITY IN INFLAMMATORY BOWEL DISEASE PATIENTS: VALIDATION OF THE GREEK VERSION

IBD (Posters)  et al.

MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY
MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY

IBD (Posters)  et al.

SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS

IBD (Posters)  et al.

LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES
LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES

IBD (Posters)  et al.

THERAPEUTIC DRUG MONITORING: PERFORMANCE OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST FOR THE QUANTIFICATION OF INFLIXIMAB IN A FINGER PRICK
THERAPEUTIC DRUG MONITORING: PERFORMANCE OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST FOR THE QUANTIFICATION OF INFLIXIMAB IN A FINGER PRICK

IBD (Posters)  et al.

CORRELATION OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY INFLIXIMAB AND ANTI-INFLIXIMAB ANTIBODIES IN A FINGER PRICK SAMPLE WITH THE REFERENCE ELISA TECHNIQUE
CORRELATION OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY INFLIXIMAB AND ANTI-INFLIXIMAB ANTIBODIES IN A FINGER PRICK SAMPLE WITH THE REFERENCE ELISA TECHNIQUE

IBD (Posters)  et al.

IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

IBD (Posters)  et al.

Item 381 - 400 / 568
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
20
21 22 23 24 25 26 27 28 29